

David Charles Hutchings

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4982445/david-charles-hutchings-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8

papers

170

citations

4

h-index

9

g-index

9

ext. papers

227

ext. citations

6.7

avg, IF

3.24

L-index

#	Paper	IF	Citations
8	The Diagnostic and Prognostic Utility of Contemporary Cardiac Magnetic Resonance in Suspected Acute Myocarditis.. <i>Diagnostics</i> , 2022 , 12,	3.8	1
7	PDE5 Inhibition Suppresses Ventricular Arrhythmias by Reducing SR Ca Content. <i>Circulation Research</i> , 2021 , 129, 650-665	15.7	2
6	The Control of Diastolic Calcium in the Heart: Basic Mechanisms and Functional Implications. <i>Circulation Research</i> , 2020 , 126, 395-412	15.7	43
5	Letter by Hutchings et al Regarding Article, "Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation : An INTERMACS Analysis". <i>Circulation: Heart Failure</i> , 2019 , 12, e006410	7.6	1
4	Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure. <i>Scientific Reports</i> , 2019 , 9, 6801	4.9	22
3	Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?. <i>Heart</i> , 2018 , 104, 1244-1250	5.1	43
2	Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. <i>Heart</i> , 2016 , 102, 1750-1756	5.1	58
1	Ventricular arrhythmias complicating hypertrophic cardiomyopathy. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012 , 73, 502-8	0.8	0